Regeneron Pharmaceuticals (NasdaqGS:REGN) recently announced a strategic in-licensing agreement with Hansoh Pharmaceuticals, acquiring rights for a dual GLP-1/GIP receptor agonist, HS-20094.

Additionally, Regeneron has entered into a licensing agreement with Hansoh Pharmaceuticals for the obesity drug candidate HS-20094, with an upfront payment of $80 million and potential future ...

Regeneron Pharmaceuticals, Inc. (REGN) on Monday said that it has entered into a strategic in-licensing agreement with ...

Major players including AbbVie, GSK, Sanofi, and Eli Lilly recently bolstered their R&D pipelines with a wave of acquisitions ...

Regeneron isn’t the only Big Pharma to spot potential in Hansoh’s obesity pipeline. Merck & Co. ended last year paying $112 ...

Regeneron Pharmaceuticals (REGN ... Hong Kong and Macau for a dual GLP-1/GIP receptor agonist, HS-20094, currently in Phase 3 testing.

has been named the winner of won the top award in the Regeneron Science Talent Sea Achyuta Rajaram 2024, America’s oldest and most prestigious science and math competition for high school ...

Regeneron Pharmaceuticals Inc. is adding to its obesity pipeline by in-licensing Hansoh Biomedical Co. Ltd.’s phase III dual ...

LOS ANGELES, CA – Regeneron Pharmaceuticals, Inc. and the Society for Science on May 17 announced that Krish Pai, 17, of Del Mar, California, received the second Regeneron Young Scientist Award ...

Regeneron has formed a corporate venture capital unit with $100 million a year to invest over the next five years in “biopharmaceutical, healthcare, and health technology” start-ups.